Drivers and Restraints Impacting the Global Cryptococcosis Treatment Market; CMI Reveals Insights upto 2026

Cryptococcosis is a fungal disease, which in severe cases, could prove to be fatal. It is generally caused by a particular species of the fungus Cryptococcus, called Cryptococcus neoformans. Cryptococcosis is said to be acquired by inhaling contagious propagule, usually present in one’s surroundings. Even though the accurate character of the contagious propagule is not known, the primary theory determines the basidiospore, which is produced in the course of sexual or asexual reproduction, to be the principal cause. Cryptococcosis disease symptoms include fatigue, fever, headache, blurred vision, and dry cough, among others. The onset of the symptoms is often sub-acute, which worsens progressively over a few weeks.

For More Information, Request FREE sample copy of Business Report: https://www.coherentmarketinsights.com/insight/request-sample/147

Two of the key complications of the disease are meningitis (brain infection) and pulmonary infection or lung infection. The occurrence of cryptococcosis is steadily increasing for a multitude of reasons, such as rising prevalence of AIDS, extended use of immunosuppressive drugs, etc. These factors are likely to propel the growth of the global cryptococcosis treatment market in the near future.

According to a report issued by the National Centre for Biotechnology Information, illnesses caused due to the Cryptococcus fungi occur on a global scale and in an extensive range of hosts, starting from patients who are strictly immunosuppressed to patients with normal immune systems. The Centers for Disease Control and Prevention (CDC) reported that around 1 million cryptococcosis cases arise across the globe, and it is estimated that the number of deaths associated with cryptococcosis is would be around 650,000 each year. Most of the cases are reported among amongst patients with complex HIV disease. However, incidence rate is high amongst the recipients of solid organ transplant and patients getting exogenous immunosuppression. Cryptococcus occurs in those with acquired and innate immunodeficiency as well.

As the AIDS population is rising at a startling rate, the likelihood of occurrence of the disease is rising proportionately. Since cryptococcosis disease is communicable in nature, and it gets transmitted from one affected person to the next, persons suffering from the disease are expected to rise in the near future. Therefore, the cryptococcosis treatment market will also show a considerable growth.

Apply Promo Code “STAYHOME” And Get Instant Discount Of USD 1000
Buy Now This Premium Report to Grow your Business @ https://www.coherentmarketinsights.com/insight/buy-now/147

Global Cryptococcosis Treatment Market Taxonomy

Based on the type of treatment, global cryptococcosis treatment market is segmented into:

• • Amphotericin B
  • Flucytosine
  •  Fluconazole
  • Others

Rising prevalence of chronic diseases to fuel the global cryptococcosis treatment market expansion

The major factors fostering the global cryptococcosis treatment market growth include the rising count of people being affected by the disease. As per UNAIDS, there is an estimated 36.7 million cases of AIDS in the world at the end of the year 2015. Rise in the prevalence of diseases such as AIDS will further amplify the demand for the cryptococcosis treatment. Cryptococcosis was classified as a rarely happening illness. However, the disease’s prevalence is currently seen to be rising across the globe. Several governments are vastly interested in eliminating the disease altogether from their respective nations. The efforts put in by governments of various regions are encouraging the players in the global market to increase their overall spend on research and development activities, in order to get superior treatment alternatives. This will further aid the global market of cryptococcosis treatment to increase at a steady pace.

Increasing prevalence of cryptococcosis in sub-Saharan Africa will drive the overall cryptococcosis treatment market growth

According to the CDC, there were an estimated 720,000 cases of HIV-related cryptococcosis reported in the sub-Saharan region of Africa in 2009, which is about three times the prevalence of the disease in all other parts of the world, combined. It is believed that the disease kills more people in this region than tuberculosis. Moreover, cryptococcosis is considered the fourth most fatal disease in the region. It is estimated to cause about 504,000 deaths per year. The occurrence of cryptococcosis in the region is growing at an alarming rate. Hence, the market in this region is expected to grow at a significant rate over the forecast period.

Special Requirements?
We value your investment and offer customization as per your requirements.

Share your precise requirements @ https://www.coherentmarketinsights.com/insight/request-customization/147

Global Cryptococcosis Treatment Market – Competitive Outlook

The major companies operating in the global cryptococcosis treatment market are Bristol-Myers Squibb Company, Sigmapharm Laboratories LLC, Janssen Biotech Inc. (Johnson & Johnson), Novartis AG, Abbott Laboratories, Valeant Pharmaceuticals Inc., Pfizer Inc., and Glenmark Pharmaceuticals.

 Key Developments

The major market players are involved in adopting different business strategies, such as gaining product approval from regulatory authorities and new product launches, in order to gain a competitive edge in the global market. For instance, in February 2019, Amplyx Pharmaceuticals, a U.S.-based pharmaceutical company, received the orphan drug designation (ODD) for APX001 from the U.S. Food and Drug Administration (FDA) Office of Orphan Product Development. This drug is being used for the treatment of cryptococcosis. In January 2018, Lupin Limited, an Indian pharmaceutical company, launched the generic version of Valeant Pharmaceutical International Inc.’s ‘Ancobon Capsules’. These capsules are indicated for infections caused by Cryptococcus.

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

To know more about us, please visit our website – www.coherentmarketinsights.com

Contact:

Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837

This content has been distributed via CDN Newswire press release distribution service. For press release enquires please mail us at contact@cdnnewswire.com.